As of June 5, 2025, Inhibikase Therapeutics Inc (IKT) reports a ROA (Return on Assets) of -27.91%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Inhibikase Therapeutics Inc's ROA (Return on Assets)
Over recent years, Inhibikase Therapeutics Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -27.91% |
| 2023-12-31 | -131.17% |
| 2022-12-31 | -72.37% |
| 2021-12-31 | -34.82% |
| 2020-12-31 | -19.28% |
This fluctuation highlights how Inhibikase Therapeutics Inc manages its efficiency in using assets to generate earnings over time.
Comparing Inhibikase Therapeutics Inc's ROA (Return on Assets) to Peers
To better understand Inhibikase Therapeutics Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Inhibikase Therapeutics Inc (IKT) | -27.91% |
| Idera Pharmaceuticals Inc (IDRA) | 281.35% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| Amgen Inc (AMGN) | 4.45% |
| Abbvie Inc (ABBV) | 3.17% |
| Enzon Pharmaceuticals Inc (ENZN) | 1.65% |
Compared to its competitors, Inhibikase Therapeutics Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.